1. National Cancer Institute. Bethesda, MD: National Institutes of Health. Nivolumab. Available from: http://www.cancer.gov/about-cancer/treatment/drugs/nivolumab. Published January 7, 2015. [Updated May 19, 2016. Cited August 25, 2016.]
2. Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy;Goldinger;Clin Cancer Res,2016
3. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study;Nakamura;J Dermatol,2016
4. Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma;Ohtsuka;JAMA Dermatol,2015
5. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies;Sibaud;Curr Opin Oncol,2016